Warning letterPosted November 25, 2025

FDA warning letter to Wells Pharma of Houston, LLC

Compounding Pharmacy/Adulterated Drug Products

FDA's record ↗

FDA posted a warning letter to Wells Pharma of Houston, LLC on November 25, 2025; the letter is dated November 7, 2025. Subject: Compounding Pharmacy/Adulterated Drug Products. Issuing office: Center for Drug Evaluation and Research (CDER).

On the record

Company
Wells Pharma of Houston, LLC
Subject
Compounding Pharmacy/Adulterated Drug Products
Issuing office
Center for Drug Evaluation and Research (CDER)
Letter dated
2025-11-07
Posted by FDA
2025-11-25
Source
FDA warning letters ↗

CFR cited

The record cites 10 sections of 21 CFR Parts 200, 201, 210, 211 and 310.

The full record

An account shows the violations FDA described and each CFR section it cited.

What a warning letter is

A warning letter is FDA's notice to a company that it found significant violations of federal requirements. FDA asks for a written response, normally within 15 working days. The letter is advisory: it states the agency's position and is not a final agency action.

More

Watch Wells Pharma of Houston, LLC

A free account shows the last 7 days of every record. Pro adds a watchlist: one email when FDA acts on a company you name.

From FDA warning letters. The record may have changed since it was read.

Approve Suite is not affiliated with FDA, or with Wells Pharma of Houston, LLC.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.